Companies, health organizations and investors
Engage a specialized mandate to find, evaluate or bring an opportunity to market with less uncertainty.
Explore a mandate→Scientific intelligence · Market access · Venture building
Science.
Health. Impact.
We turn diagnostic and prevention technologies into decisions, partnerships and market pathways between the United States and Latin America.
We work with diagnostic companies, laboratories, universities, health organizations and investors through specialized mandates in scouting, scientific-commercial diligence, market access and venture building.
Innovation network: Boston · Cambridge · ProvidenceCommercial reach: Colombia · Latin America
From evidence to adoption
- 01IdentifyScience aligned with a real need
- 02ValidateEvidence, clinical utility and buyer
- 03StructureProduct, partnership and market pathway
- 04ScaleMilestones, disciplined capital and impact
Boston · Cambridge · Providence↔Colombia · Latinoamérica
Scientific rigorClinical utilityCommercial viabilityResponsible impact
Two entry points
Two clear ways to work with ABG.
Researchers, universities and technology transfer offices
Submit a non-confidential technology to assess its scientific, clinical and commercial fit with ABG's thesis.
Submit a technology→Paid services
Actionable decisions. Concrete deliverables.
Every mandate begins with a defined question, accountable owner, deliverable and decision pathway.
BioScout
Scientific-commercial radar aligned with a strategic need.
- Search thesis and landscape
- Prioritized pipeline
- Shortlist with selection rationale
BioDiligence
Integrated assessment before committing time, reputation or capital.
- BioVenture Score
- Risks and Kill Criteria
- Recommendation and next gates
LatAm Market Access
Selective country-by-country entry and adoption pathway.
- Buyer and partner map
- Regulatory-commercial pathway
- First-pilot design
Venture Building
Disciplined company creation around a validated need.
- Thesis and business model
- Governance and milestones
- Capital and partnership pathway
Our focus
Precision health with a clear path to adoption.
We begin where evidence can become earlier, more precise and more useful decisions for patients, professionals and health systems.
- Biomarkers
- Genomics and clinical data
- Responsible AI
- Enabling technologies
Advanced diagnostics
Technologies that improve the precision, speed or accessibility of a diagnostic decision.
Early detection
Solutions that identify disease or risk when intervention can create greater impact.
Personalized prevention
Evidence-based tools for risk stratification, screening, monitoring and intervention.
Our model
Value today. Assets for tomorrow.
We clearly separate services that generate revenue from day one from selective participation that may create long-term enterprise value.
Operating engine · revenue from day one
Paid services and commercialization
Specialized mandates that help clients decide better, reduce risk and build a market pathway.
- BioScout and BioDiligence
- Commercial access and partnerships
- Sponsored Venture Building
Asset engine · long term
Venture building and selective participation
Equity, licenses, options and regional rights only in opportunities that clear a rigorous assessment.
- Milestone-based development
- Partnerships and new companies
- Capital aligned with evidence
ABG is neither a traditional fund nor a generalist consultancy: it integrates scientific intelligence, commercial access and company creation.
The ABG method
Visible rigor in every decision.
Artificial intelligence expands our capacity; evidence, expert judgment and human authority govern decisions.
Mandate Gate M0
Defines who engages us, the question, deliverable and success criterion.
BioVenture Score
Integrates scientific merit, clinical utility, market, regulation, team and capital.
Stage-Gates + Kill Criteria
Advances through evidence and stops opportunities that do not justify more resources.
Traceable human decision
AI supports; the team and experts retain review, accountability and authority.
Why ABG
A complete path across science, buyer and execution.
Science + market
We assess scientific merit and buyer needs from the beginning.
International bridge
We connect U.S. innovation ecosystems with selective execution in Latin America.
Capital discipline
Every next investment of time or money requires new evidence.
Responsible AI
Expanded capacity with expert review and human decisions.
Leadership team
Three perspectives. One decision.
Business leadership, scientific judgment and medical-commercial experience applied to the same opportunity.
Francisco Aragón
Founder and Executive President
Entrepreneur · Corporate governance · Capital discipline
Leads vision, governance, risk appetite, strategic relationships and company building.
francisco.aragon@advancebioventures.comAngélica Aragón Vásquez
Director of Science and Innovation
Biologist · Master's in Management · Master's in Biotechnology
Leads scouting, evidence assessment, the innovation pipeline and responsible AI adoption.
angelica.aragon@advancebioventures.comMauricio Pérez Gil
Founding Partner and Director of Business Development and Strategic Alliances
Neurologist · Medical-scientific and commercial experience
Leads clients, medical-commercial utility, partnerships, buyers and market-access pathways.
mauricio.perez@advancebioventures.comLet's talk
A mandate, a technology or a partnership can begin here.
Tell us what you need to decide, what opportunity you are evaluating or what technology you would like to submit. The first contact must be non-confidential.
CompaniesHealth organizationsResearchersUniversitiesInvestorsPartners